June 23, 2023
Thoughts Following Asembia 2023 Part 2: Fragmentation and Disruption in the...
3 Minute Read
Channel expert Bill Roth explores how we are seeing an unprecedented level of changes and transformation in the industry.
Blog
June 8, 2023
Monitoring the Gross-to-Net Impacts of WAC Price Increases
2 Minute Read
Manufacturers considering taking a WAC price increase this year should be aware of the impact on their GTN line items.
May 31, 2023
Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and...
3 Minute Read
Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.
May 15, 2023
Thoughts Following Asembia 2023 Part 1: Exploring the New Pharmacy Landscape
2 Minute Read
Channel expert Bill Roth explores how specialty pharmacy has evolved and their take on the current landscape and insights for pharmaceutical organizations.
April 24, 2023
340B Contract Pharmacy Restrictions, M&A Funding in Biotech & FDA Accelerated...
6 Minute Read
Updates on 340B Contract Pharmacy Restriction Updates, M&A and Venture Capital Funding in Biotech, and Stricter Accelerated Approval Criteria Proposed for FDA.
April 17, 2023
Why Modernize Your Gross-to-Net? 5 Benefits of Pharma Digital Transformation
2 Minute Read
In the current pharma landscape, more than 80% of manufacturers still rely on manual processes to accrue, forecast, and report their gross-to-net (GTN) deductions. This is primarily because of...
April 7, 2023
State Pricing Transparency Reporting – Part 2
3 Minute Read
Explore the best practice recommendations regarding compliance for SPTR.
March 29, 2023
Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act Guidance...
5 Minute Read
Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act, and Operationalizing Medicare Inflationary Rebates.
March 21, 2023
Perspectives on Pharma Market Access Launch Challenges & Strategy Part 2
9 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.